IRIS
ARMUZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 6.356
EU - Europa 1.730
AS - Asia 919
AF - Africa 73
SA - Sud America 4
OC - Oceania 1
Totale 9.083
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 6.337
FI - Finlandia 528
SG - Singapore 475
IE - Irlanda 413
CN - Cina 253
FR - Francia 211
DE - Germania 161
NL - Olanda 119
IN - India 116
GB - Regno Unito 74
NG - Nigeria 69
IT - Italia 51
RU - Federazione Russa 45
SE - Svezia 42
BE - Belgio 29
CZ - Repubblica Ceca 25
IR - Iran 21
CA - Canada 17
HK - Hong Kong 14
TR - Turchia 12
IL - Israele 11
JP - Giappone 9
RO - Romania 5
EG - Egitto 4
ES - Italia 4
BG - Bulgaria 3
BR - Brasile 3
CH - Svizzera 3
PL - Polonia 3
AE - Emirati Arabi Uniti 2
AT - Austria 2
EE - Estonia 2
MX - Messico 2
PH - Filippine 2
TW - Taiwan 2
UA - Ucraina 2
AR - Argentina 1
AU - Australia 1
BN - Brunei Darussalam 1
DK - Danimarca 1
IS - Islanda 1
LU - Lussemburgo 1
MK - Macedonia 1
NO - Norvegia 1
PT - Portogallo 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
VN - Vietnam 1
Totale 9.083
Salva come PNG Salva come JPEG
Città #
Chandler 1.802
Helsinki 528
Dublin 413
Boardman 397
Ashburn 395
Lawrence 390
Princeton 390
Singapore 344
Shanghai 246
New York 213
Paris 206
Wilmington 184
Amsterdam 119
Los Angeles 114
Pune 110
London 69
Benin City 68
San Mateo 65
Ann Arbor 49
Santa Clara 37
Moscow 35
Phoenix 32
Leawood 29
Brussels 28
Brno 22
Fairfield 19
Woodbridge 19
Frankfurt am Main 16
Toronto 13
Oshnaviyeh 12
Falkenstein 11
Berlin 9
Milan 9
Munich 9
Kocaeli 8
Hanover 6
Hong Kong 6
Clifton 5
Collegeville 5
Council Bluffs 5
Norwalk 5
St Petersburg 5
Campobasso 4
Redwood City 4
Seattle 4
Tokyo 4
Atlanta 3
Beijing 3
Cambridge 3
Hirakata 3
Houston 3
Madrid 3
Miami 3
Olomouc 3
Ottawa 3
Rome 3
San Francisco 3
Sassari 3
Sofia 3
São Paulo 3
Tel Aviv 3
Bologna 2
Cairo 2
Cinisello Balsamo 2
Genoa 2
Hadera 2
Istanbul 2
Iztapalapa 2
Las Vegas 2
Montichiari 2
Mumbai 2
Qingdao 2
Sale Marasino 2
Stockholm 2
Tallinn 2
Toulouse 2
Turin 2
Vienna 2
Warsaw 2
Assiut 1
Augusta 1
Bandar Seri Begawan 1
Belgrade 1
Bitola 1
Buenos Aires 1
Buffalo 1
Cary 1
Chennai 1
Chicago 1
Clearwater 1
Copenhagen 1
Craiova 1
Dalsjoefors 1
Delhi 1
Dubai 1
Gatchina 1
Hangzhou 1
Harlow 1
Henderson 1
Ho Chi Minh City 1
Totale 6.565
Salva come PNG Salva come JPEG
Nome #
A liophylized and inactivated colture of Lactobacillus acidophilus increases Helicobacter pylori eradication rate 63
Adalimumab in active ulcerative colitis: A "real-life" observational study 57
Use of biosimilars in inflammatory bowel disease: a position update of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 52
Expert consensus paper on the use of Vedolizumab for the management of patients with moderate-to-severe Inflammatory Bowel Disease 51
13C-Breath Tests in the study of microsomal liver function 50
13C-breath tests in the study of mitochondrial liver function 50
Effectiveness of Mesalazine, Thiopurines and Tumour Necrosis Factor Antagonists in Preventing Post-Operative Crohn's Disease Recurrence in a Real-Life Setting 47
Effect of tight control management on Crohn's disease (CALM): a multicentre, randomised, controlled phase 3 trial 45
3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management 45
A machine-learning parsimonious multivariable predictive model of mortality risk in patients with Covid-19 44
Long-term Combination Therapy with Infliximab Plus Azathioprine Predicts Sustained Steroid-free Clinical Benefit in Steroid-dependent Ulcerative Colitis 44
Use of corticosteroids and immunosuppressive drugs in inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease 43
Discontinuation of Infliximab in Patients With Ulcerative Colitis Is Associated With Increased Risk of Relapse: A Multinational Retrospective Cohort Study 43
FOXP3(+) T Regulatory Cell Modifications in Inflammatory Bowel Disease Patients Treated with Anti-TNF alpha Agents 42
Infliximab in Steroid-dependent Ulcerative Colitis: Effectiveness and Predictors of Clinical and Endoscopic Remission 41
A lyophilized and inactivated culture of Lactobacillus acidophilus increases Helicobacter pylori eradication rates 40
A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: infliximab and surgery 40
H-pylori poliantibiotic resistant strains in dyspeptic patients not eradicated by two consecutive triple eradication regimens 39
Review article: The pharmacokinetics and pharmacodynamics of drugs used in inflammatory bowel disease treatment 39
A transition clinic model for inflammatory bowel disease between two tertiary care centers: outcomes and predictive factors 38
Long-Term Safety of In Utero Exposure to Anti-TNFα Drugs for the Treatment of Inflammatory Bowel Disease: Results from the Multicenter European TEDDY Study 38
Efficacy and Safety of Upadacitinib in a Randomized Trial of Patients With Crohn's Disease. Sandborn WJ, Feagan BG, Loftus EV Jr, Peyrin-Biroulet L, Van Assche G, D'Haens G, Schreiber S, Colombel JF, Lewis JD, Ghosh S, Armuzzi A, Scherl E, Herfarth H, Vitale L, Mohamed MF, Othman AA, Zhou Q, Huang B, Thakkar RB, Pangan AL, Lacerda AP, Panes J 37
Acute pancreatitis and parathyroid carcinoma: a case report and literature review 37
Long-term scheduled therapy with infliximab in inflammatory bowel disease 37
ECCO Guidelines on Therapeutics in Crohn's Disease: Surgical Treatment 37
The PROSIT-BIO Cohort: A Prospective Observational Study of Patients with Inflammatory Bowel Disease Treated with Infliximab Biosimilar 37
The role of tumour necrosis factor in the pathogenesis of immune-mediated diseases 36
H-pylori gastric infection and rheumatic diseases 36
3-day antibiotic therapy with azithromycin and tinidazole plus lansoprazole or pantoprazole to cure H-pylori infection 36
Role of helicobacter pylori in gastroesophageal reflux disease 36
Difference in treatment outcomes between clinical trials and "real-life" clinical practice: ustekinumab in ulcerative colitis 36
Safety of treatments for inflammatory bowel disease: Clinical practice guidelines of the Italian Group for the Study of Inflammatory Bowel Disease (IG-IBD) 36
The intercellular adhesion molecule-1 polymorphisms in IBD 35
HELICOBACTER-PYLORI GASTRITIS WITH CYTOTOXIN ASSOCIATED PROTEIN ANTIBODIES (CAGA) - A COMPUTER-AIDED EVALUATION OF INFLAMMATORY CELL INFILTRATION IN THE LAMINA PROPRIA, ATROPHIC GASTRITIS AND ACQUIRED MALT 35
Disease patterns in late-onset ulcerative colitis: Results from the " IG-IBD ""AGED study""" 35
Third European Evidence-based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, Diagnosis, Extra-intestinal Manifestations, Pregnancy, Cancer Surveillance, Surgery, and Ileo-anal Pouch Disorders 34
Helicobacter pylori eradication ameliorates migraine: An extended follow up study 34
Anti-CagA antibodies are associated with atrophic gastritis in a population at high gastric cancer risk: a morphometric study by computerized image analysis 34
Adherence to international guidelines for the management of Helicobacter pylori infection among gastroenterologists and gastroenterology fellows in Italy: A Survey of the Italian Federation of Digestive Diseases - FISMAD 34
Achievement of sustained deep remission with adalimumab in a patient with both refractory ulcerative colitis and seronegative erosive rheumatoid arthritis 34
Activities related to inflammatory bowel disease management during and after the coronavirus disease 2019 lockdown in Italy: How to maintain standards of care 33
Infliximab in Steroid-Dependent Ulcerative Colitis 33
Multidisciplinary Management of Spondyloarthritis-Related Immune-Mediated Inflammatory Disease 33
Real-life effectiveness of ustekinumab in inflammatory bowel disease patients with concomitant psoriasis or psoriatic arthritis: An IG-IBD study 33
C-13-methionine breath tests for mitochondrial liver function assessment 32
Anti TNF-α therapy for ulcerative colitis: current status and prospects for the future 32
Advances in extracorporeal detoxification by MARS dialysis in patients with liver failure 32
Fecal calprotection in first-degree relatives of patients with ulcerative colitis 32
Antibiotic resistance of H-pylori strains obtained by dyspeptic patients not eradicated by two consecutive eradication regimens 32
Long-Term Scheduled Therapy with Infliximab in Inflammatory Bowel Disease 32
Efficacy of a multistep strategy for Helicobacter pylori eradication 32
C-13 urea breath test for predicting resistance to therapy in Helicobacter pylori infection 32
Higher vs Standard Adalimumab Induction Dosing Regimens and Two Maintenance Strategies: Randomized SERENE CD Trial Results 32
Activity of Crohn's disease and small bowel contract-enhanced ultrasound findings 32
INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS ON ANTI TNF-ALPHA THERAPY: RESPONSE TO THE INFLUENZA A/H1N1 VACCINE 31
Diet and Nutrients in Gastrointestinal Chronic Diseases 31
Objective comparison of vedolizumab and ustekinumab effectiveness in Crohn's disease patients failure to TNF-alpha inhibitors 31
Aminopyrine and methacetin 13C-breath tests to assess hepatic function in HCV-related chronic liver disease 31
C-13-methacetin breath test in patients with nonalcoholic steatohepatitis 31
Complex Perianal Crohn's Disease: Effectiveness of Combined Seton Placement and Anti-TNF Alpha Agents in Monotherapy or in Association With Immunosuppressants 31
Adalimumab in the treatment of immune-mediated diseases 31
Hepatic mitochondrial beta-oxidation in patients with Nonalcoholic-Steatohepatitis (NASH) assessed by 13C-octanoate breath test 31
Dual Targeted Therapy in Patient With Extensive Crohn's Disease: Different Response at Distinct Location 31
Are we choosing wisely for inflammatory bowel disease care? The IG-IBD choosing wisely campaign 31
Young GI angle: Should I go abroad? 30
Gender affects C-13-ketoisocaproic acid breath test 30
Impact of SARS-CoV-2 Infection on the Course of Inflammatory Bowel Disease in Patients Treated with Biological Therapeutic Agents: A Case-Control Study 30
COMPLEX PERIANAL FISTULIZING CROHN'S DISEASE: LONG-TERM EFFICACY OF COMBINED SETON PLACEMENT AND ANTI TNF-ALPHA AGENTS ALONE OR ASSOCIATED WITH IMMUNOSUPPRESSANTS 30
The management of inflammatory bowel diseases in the era of COVID-19 pandemic: When "non-urgent" does not mean "deferrable" 30
Two-year effectiveness and safety of golimumab in ulcerative colitis: An IG-IBD study 30
Helicobacter pylori-related diseases 30
Prevention of postoperative recurrence with azathioprine or infliximab in patients with Crohn's disease: an open-label pilot study 30
Reply to Dr. Kotze's and Dr. Yamamoto's letter 30
Serum triiodothyronine-to-thyroxine (T3/T4) ratio predicts therapeutic outcome to biological therapies in elderly IBD patients 30
anti-TNF agents as therapeutic choice in immune-mediated inflammatory diseases: focus on adalimumab 30
A novel pathogenic role for microvasculature in inflammatory bowel disease 30
Non-invasive assessment of human hepatic mitochondrial function through the C-13-methionine breath test 30
Incidence and symptoms related to Helicobacter pylori infection in dyspeptic patients 29
Haplotypic analysis of heat shock protein 70 (HSP70) single nucleotide polymorphisms (SNPs) in susceptibility and phenotype of inflammatory bowel disease (IBD) 29
Cancer Risk in Inflammatory Bowel Disease: A 6-Year Prospective Multicenter Nested Case-Control IG-IBD Study 29
Hepatic mitochondrial function assessment through C-13-methionine and C-13-sodium octanoate breath tests 29
Levofloxacin based regimens for the eradication of Helicobacter pylori 29
COVID-19 Vaccination Willingness and Hesitancy in Patients With Inflammatory Bowel Diseases: Analysis of Determinants in a National Survey of the Italian IBD Patients' Association 29
Usefulness of C-13-methionine breath test as a non-invasive and dynamic tool to evaluate residual hepatic mitochondrial function 29
Gender affects 13C-ketoisocaproic breath test for liver mitochondrial function 29
Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery? 29
Study of liver function in healthy elderly subjects using the C-13-methacetin breath test 29
Role of sucralfate in gastrointestinal diseases 29
Update on the management of inflammatory bowel disease: specific role of adalimumab 29
DISAPPEARANCE OF GASTRIC ACQUIRED MALT AND REGRESSION OF LOW-GRADE B-CLL GASTRIC LYMPHOMA BY MEAN ANTI-H-PYLORI TREATMENT 29
Long-term outcomes of acute severe ulcerative colitis in the rescue therapy era: A multicentre cohort study 29
Efficacy and safety of tofacitinib dose de-escalation and dose escalation for patients with ulcerative colitis: results from OCTAVE Open 29
Use of biosimilars in inflammatory bowel disease: Statements of the Italian Group for Inflammatory Bowel Disease 29
Successful induction of clinical response and remission with certolizumab pegol in Crohn's disease patients refractory or intolerant to infliximab: a real-life multicenter experience of compassionate use 29
A multistep assessment of human liver mitochondrial function through C-13-ketoisocaproate and C-13-octanoate breath tests 29
Treatment satisfaction, preferences and perception gaps between patients and physicians in the ulcerative colitis CARES study: A real world-based study 28
New developments in biologics therapy: what about from the medical point of view? 28
Editorial: withdrawal of anti TNF-alpha - are we ready for biological therapy cycling? 28
New concepts concerning management of Helicobacter pylori infection: 2 years after the Maastricht Consensus Report 28
Lipid Profiles in Patients With Ulcerative Colitis Receiving Tofacitinib-Implications for Cardiovascular Risk and Patient Management 28
Totale 3.441
Salva come PNG Salva come JPEG
Categoria #
all - tutte 77.141
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 77.141
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20209 0 0 0 0 0 0 0 0 0 0 0 9
2020/2021334 2 3 1 4 0 114 41 21 74 42 1 31
2021/2022227 6 2 11 43 3 0 7 24 19 19 50 43
2022/20235.208 842 55 423 571 430 547 7 531 960 455 333 54
2023/20243.336 219 318 781 260 112 383 184 108 26 217 337 391
2024/202553 53 0 0 0 0 0 0 0 0 0 0 0
Totale 9.167